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Traceless protein delivery with an efficient recyclable
nanocarrier†
Xuanjun Wu,a Yunlong Song,b Jiahuai Han,b Liu Yanga and Shoufa Han*a
Intracellular delivery is a prerequisite for the efficacy of many pharmaceutical proteins. Herein, vitamin B6
(pyridoxal-5’-phosphate, PLP) functionalized calcium phosphate (CP) is used as the bio-recyclable nano-
carrier for delivery of proteins into cells. Proteins could be loaded on/released from PLP-CP via for-
mation/hydrolysis of pH sensitive aldimine bridging lysine and surface-displayed PLP. The loaded proteins
could be delivered into the cytosol of HeLa, HepG2 and L929 cells where the carrier could be meta-
bolized into endogenous metabolites of Ca2+, HPO4
2−, and vitamin B6. PLP-CP mediated cell transduction
is 10–40 folds more efficient than TAT which is a widely used cell penetrating peptide, demonstrating the
utility of PLP-CP as the traceless platform for high-efficiency delivery of proteins into mammalian cells.
Introduction
Introduction of bioactive proteins into cells is fundamental for
a number of biomedical applications such as enzyme replace-
ment therapy and immunotherapy targeting subcellular anti-
gens.1 Given the impermeability of cell membranes to
macromolecular proteins, tools enabling efficient cellular
delivery would greatly advance the utility of many proteins.2
Accordingly, distinct strategies relying on synthetic carriers or
cell penetrating peptides,3 e.g. TAT derived from the transduc-
tion domain of HIV, have been developed to facilitate intra-
cellular protein delivery.
Nanomaterials are promising drug carriers and yet there is
increasing concern regarding their biosafety.4 For instance,
mesoporous silica nanoparticles (MSNs), widely considered to
be biocompatible,5 were shown to be resistant to biodegradation
within cells and were accumulated in various organs.6 Recently,
chemically modified MSNs were employed for delivery of pro-
teins into cells via endocytosis, an intrinsic cellular pathway
that can actively transport nanoparticles into the cells.7 We
reported the cytosolic delivery of proteins into mammalian cells
with aldehyde-displaying MSNs via lysosomal pH triggered
protein release from the silica carrier.7e Herein, a bio-recyclable
nanocarrier, assembled from calcium phosphate (CP) and
pyridoxal-5′-phosphate (PLP), is used for highly efficient and
traceless delivery of proteins into living cells where the carrier
could be degraded into Ca2+, HPO4
2−, and PLP which is the bio-
logically active form of vitamin B6 (Scheme 1).
Results and discussion
Synthesis and characterization of PLP-CP
Calcium phosphate (CP), a constituent of bones, is an ideal
biocompatible material. Apart from being widely used for DNA
transfections in cell biology studies,8 nanosized CP was
Scheme 1 Intracellular protein delivery mediated by PLP-CP. Proteins are
loaded on PLP-CP via formation of multivalent aldimines featuring an intra-
molecular H-bond (shown in red). The protein/PLP-CP composite is subjected to
lysosomal pH promoted protein release and dissociation of PLP-CP into
endogenous metabolites.
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recently employed as the carriers of dyes or chemotherapeutics
for imaging or treatment of cancers.9 As the cofactor of amino-
transferases, PLP interacts with the ε-amino group of the
lysine residue located in the catalytic sites to give aldimine.
The aldimino nitrogen forms an internal hydrogen bond with
the neighbouring phenolic moiety of PLP, which stabilizes the
PLP–lysine complex.10 Inspired by the unique aldimine chem-
istry of PLP and in order to avoid the use of inert MSNs, we
sought to construct PLP functionalized CP (PLP-CP) which
could be used as a biocompatible nanocarrier for efficient
protein loading driven by formation of aldimines and release
of the payload inside cells via lysosomal acidity mediated dis-
sociation of the protein–carrier composites (Scheme 1).
PLP-CP was easily prepared via a one-step reaction by neutral-
ization of an aqueous solution of CaCl2–Na2HPO4–PLP (3 : 5 : 1,
molar ratio) (pH 1) with addition of triethylamine under vigor-
ous stirring. The nanocarrier was collected by centrifugation,
washed with water and then lyophilized. The scanning electron
microscopy (SEM) image showed that PLP-CP was rod-like par-
ticles with a typical length of 150 nm (Fig. 1A). PLP-CP displayed
the yellow color of PLP whereas CP free of PLP was colorless,
suggesting the incorporation of PLP into the as-prepared carrier.
To quantify the levels of doped PLP, PLP-CP was treated with an
EDTA solution to liberate the embedded PLP by competitive che-
lation of Ca2+ (ESI†). UV-vis absorption of the resulting solution
showed that 4% PLP (w/w) was present in the nanocarrier
(Fig. S2, ESI†). Additionally, it was shown that the zeta potential
of PLP-CP in distilled water is −9.0 mV whereas that of CP is
3.5 mV (Fig. S3, ESI†), suggesting that anionic PLP was displayed
on the surface of PLP-CP. These data demonstrated that PLP was
successfully incorporated into PLP-CP. It is noteworthy that the
contents of PLP in the nanocarrier can be easily modulated by
altering the ratio of PLP to Na2HPO4 in the aforementioned reac-
tion medium (Fig. S1, ESI†).
Colloidal stability is a key factor for the applications of
nanoscaled materials. The morphology of PLP-CP was moni-
tored using SEM over the storage time. No agglomeration was
observed on PLP-CP before and after storage at rt in PBS for
one month (Fig. 1B), revealing the beneficial role of PLP in
maintaining the high colloidal stability of PLP-CP.
Interaction of proteins with PLP-CP
Traditional imines are labile to hydrolysis in aqueous media.
In contrast, PLP readily complexes with lysine in the enzyme
active sites under physiological conditions. In addition, the
pyridoxal–polysaccharide conjugate has been employed for
protein cross-linking.11 As such, we anticipated that loading of
proteins on PLP-CP could be facilitated owing to the formation
of multivalent PLP–lysine complexes at the interface of
protein–nanocarrier. To verify the role of PLP in protein cap-
turing, PLP-CP and CP were respectively incubated with bovine
serum albumin (BSA), fluorescein isocyanate-labelled BSA
(BSA-FITC), bovine pancreatic ribonuclease (RNase), and FITC-
labelled RNase (RNase-FITC) in PBS for 12 h. The resulting
protein/carrier composite was harvested by centrifugation,
rinsed in PBS, and then analyzed by the Bradford assay to
quantitate the levels of proteins absorbed on the carriers. As
shown in Fig. 2, the amounts of proteins on each mg of
PLP-CP were significantly higher (40–80 μg mg−1) than that on
CP (0–10 μg mg−1). Additionally, the levels of loaded proteins
closely correlated with the contents of PLP doped in the nano-
carrier (Fig. S5, ESI†). In a separate experiment, PLP-CP/eGFP
was incubated in fetal bovine serum (FBS). The time course
study showed that the amounts of eGFP released into FBS were
small post 6 h incubation (Fig. S6, ESI†), suggesting the stabi-
lity of the protein–carrier composites in serum. Collectively,
the results confirmed the critical role of PLP in efficient
protein loading on the nanocarrier.
Lysosomes are characterised by acidic luminal pH (6.0–4.0).
Linkers labile to acidic pH, e.g. hydrazones and orthoesters,
are often integrated with various pH-responsive drug delivery
systems.12 Albeit poised to hydrolysis in acidic media, imines
have been largely unexplored in delivery of therapeutic
Fig. 1 Characterization of PLP-CP. (A) SEM images of PLP-CP and CP (scale bar:
100 nm); (B) SEM images of PLP before and after storage in PBS at rt for one
month (bar: 100 nm).
Fig. 2 Efficiency of protein loading on PLP-CP vs. CP. PLP-CP and CP were
respectively added to PBS containing BSA, BSA-FITC, RNase, or RNase-FITC
(10 mg ml−1) to a final concentration of 1 mg ml−1. The solutions were incu-
bated at 4 °C for 12 h, and then centrifuged. The pellets were re-dispersed in
water and then analyzed by the Bradford assay to determine the levels of pro-
teins loaded on carriers. The experiments were repeated three times and the
error bars show the standard deviations.
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entities.13 To probe pH mediated protein release, PLP-CP/
RNase-FITC was incubated in Na2HPO4–H3PO4 buffer of
various pHs where FITC served as the fluorescence tag to allow
tracking of proteins. A portion of the mixture was centrifuged,
and the levels of protein that remained on the pellet were
determined by fluorometry as a function of incubation time.
Fig. 3 revealed the accelerated release of RNase-FITC from
PLP-CP under acidic conditions, which is consistent with the
proposed lysosomal acidity mediated protein release
(Scheme 1).
PLP-CP mediated delivery of protein into mammalian cells
PLP-CP was assessed for its capability to deliver proteins into
living cells. Human hepatoma cells (HepG2) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with RNase-FITC or PLP-CP/RNase-FITC for 4 h. Fluorescence
microscopic images showed that FITC signal was present in
cells treated with PLP-CP/RNase-FITC whereas no fluorescence
was observed in cells cultured with RNase-FITC (Fig. S7–S8,
ESI†), demonstrating the effectiveness of PLP-CP in the deli-
very of hydrophilic protein into live cells.
We further explored the impact of cell lines on PLP-CP
mediated protein transduction. L-Asparaginase (ASP) fused
with N-terminal eGFP (ASP-eGFP) and RNase-FITC were used
as the model proteins. RNase is a small protein (13.7 kDa)
whereas ASP is a large protein composed of four identical sub-
units (160 kDa) and has been marketed as an anticancer drug
for the treatment of acute lymphoblastic leukemia. HeLa,
HepG2 and L929 cells pre-loaded with DAPI were respectively
cultured with PLP-CP/RNase-FITC or PLP-CP/ASP-eGFP for
2–10 h and then stained with LysoTracker Red for 15 min. The
signals of RNase-FITC and ASP-eGFP were both clearly and
universally present in the cell populations after 2 h of incu-
bation (Fig. S9, ESI†), revealing the capability of PLP-CP to
ferry different sized proteins into a variety of mammalian
cells. LysoTracker Red is a lysosome-specific dye and DAPI is a
nucleus-staining dye. Confocal microscopy images of indivi-
dual cells of HeLa, HepG2 and L929 at different stages of
incubation showed that the colocalization of RNase-FITC
or ASP-eGFP signals with LysoTracker Red was negligible
post 2 h incubation. The colocalization increased substantially
after 4 h culturing and was then attenuated upon
prolonged 10 h incubation (Fig. 4). The time dependent co-
localization patterns suggested that the payloads were initially
internalized into lysosomes and then translocated into the
cytosol. Taken together, these data indicated that PLP-CP
could be used for the delivery of proteins into the cytosol of
mammalian cells.
Reactivity of proteins delivered into cells by PLP-CP
Proteases are abundantly located in lysosomes. It is critical
that the internalized PLP-CP/protein nanocomposites could
relocate from lysosomes into the cytosol to avoid significant
lysosomal proteolysis. As eGFP fluorescence is dependent on
the structural integrity,14 the intense eGFP fluorescence within
cells transduced with PLP-CP/eGFP or PLP-CP/ASP-eGFP
suggested that the internalized eGFP remained structurally
intact (Fig. 4). To further determine whether a protein deli-
vered by PLP-CP remained bioactive inside cells, HeLa, L929
and HepG2 cells were respectively cultured with PLP-CP/
β-galactosidase and then stained with X-Gal which is a
Fig. 3 pH dependent protein release from PLP-CP. PLP-CP/RNase-FITC was
spiked into Na2HPO4–H3PO4 (100 mM) of indicated pHs to a final concentration
of 2.5 mg ml−1 and then incubated for 0–30 min. The fluorescence emission of
protein that remained on the carrier was acquired at the indicated time points
of incubation (λex at 488 nm).
Fig. 4 Time dependent intracellular distribution of PLP-CP/RNase-FITC and
PLP-CP/ASP-eGFP. HeLa, HepG2 and L929 cells pre-stained with DAPI (1 μM)
were respectively incubated in DMEM containing PLP-CP/RNase-FITC (25 μg ml−1)
or PLP-CP/ASP-eGFP (25 μg ml−1) for 2–10 h, and then stained with Lyso-
Tracker Red (1 μM) for 15 min. The cells were analyzed by fluorescence confocal
microscopy to pinpoint the subcellular locations of internalized proteins.
A merge of Lysotracker Red (in red) and ASP-eGFP/RNase-FITC (in green) is
shown in yellow.
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chromogenic substrate of β-galactosidase. Deep-blue staining
was observed in all the cell lines that have been treated with
PLP-CP/β-galactosidase while no color formation could be
detected in the control cells (Fig. 5). Compared to L929 cells,
HepG2 is a cell line derived from macrophages which efficien-
tly internalize various vesicles such as pathogens and viruses.
The intense color within HepG2 relative to that of L929 shown
in Fig. 5 implies that cellular uptake of protein-loaded PLP-CP
may differ among cells lines. The differential staining patterns
of the cells treated with or without β-galactosidase/PLP-CP
showed that β-galactosidase delivered into the mammalian
cells retained its catalytic activity.
Efficiency of protein delivery mediated by PLP-CP vs. TAT
TAT peptide has been widely used to facilitate cellular delivery
of various cargos.3g To discern protein transduction mediated
by PLP-CP vs. TAT, HepG2 cells were respectively transduced
with eGFP, PLP-CP/eGFP or TAT-eGFP which is a fusion
protein with NH2-terminal TAT peptide. As expected, cells
treated with TAT-eGFP exhibited considerable fluorescence
emission intensity whereas no fluorescence was observed in
cells treated with eGFP (Fig. 6). Fig. 6 illustrates the unbiased
subcellular distribution of TAT-eGFP, e.g. in the cytosol and
the nucleus, which is consistent with previous observations.3i
In contrast, cells cultured with PLP-CP/eGFP displayed intense
punctate fluorescence largely located in the cytosol (Fig. 4 and
6), suggesting that PLP-CP preferentially ferries proteins into
the cytosol, which is desirable for the efficacy of many thera-
peutic proteins.
We then quantify protein internalization by flow cytometry.
HeLa, L929 and HepG2 cells were independently cultured with
equal amounts of TAT-eGFP, free eGFP, or eGFP pre-loaded on
PLP-CP. As anticipated, the overall fluorescence intensity
within cells treated with TAT-eGFP is moderately higher than
control cells treated with or without eGFP (Fig. 7). Surprisingly,
the uptake of PLP-CP/eGFP into the three cell lines was dra-
matically greater than TAT-eGFP under the assay conditions.
The mean intracellular fluorescence of HeLa and HepG2 cells
treated with PLP-CP/eGFP was roughly 40 folds higher than
that of the corresponding cells treated with TAT-eGFP while
L929 cells transduced with PLP-CP/eGFP displayed 10-fold
enhancement in the intracellular fluorescence as compared to
L929 cells cultured with TAT-eGFP (Fig. 7). The superior
efficacy of PLP-CP over TAT proves that PLP-CP is a highly
efficient carrier for the delivery of proteins into mammalian
cells.
Cytotoxicity of PLP-CP
Lastly, PLP-CP was evaluated for its potential cytotoxicity by a
trypan blue exclusion test. No toxic effects of PLP-CP were identi-
fied on the viability of HepG2 cells at doses up to 100 μg ml−1
after incubation for 0–24 h (Fig. 8), suggesting that PLP-CP is
of low cytotoxicity.
Conclusions
PLP-CP, vitamin B6 functionalized calcium phosphate, effec-
tively delivers proteins into the cytosol of mammalian cells
with an efficiency 10–40 folds higher than that of TAT, a cell
penetrating peptide widely used for cellular delivery. Com-
pared with previous efforts utilizing biologically/chemically
modified proteins (e.g. TAT fused protein) or synthetic vectors
comprised of abiotic components,3 our system uses intact pro-
teins, which could be released from PLP-CP in a pH dependent
manner, and a “green” carrier that could be metabolized into
safe and endogenous species of living systems. With the ease
of carrier synthesis and the ubiquitous presence of lysine in
Fig. 6 Intracellular delivery of eGFP mediated PLP-CP vs. TAT. L929 cells were
respectively cultured for 4 h in DMEM (1 ml) supplemented with eGFP (5 μg),
TAT-eGFP (5 μg) or eGFP (5 μg) loaded on PLP-CP. The cells were washed with
PBS, and examined by confocal fluorescence microscopy.
Fig. 5 Activity of β-galactosidase delivered into cells by PLP-CP. HeLa, HepG2
and L929 cells were respectively cultured in DMEM spiked with free β-galactosi-
dase (25 μg ml−1) or β-galactosidase loaded on PLP-CP (25 μg ml−1) for 4 h. The
cells were washed with PBS, incubated in fresh DMEM containing X-gal
(100 μM) for 12 h and then photographed.
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proteins, PLP-CP would be of practical utility as the traceless
nanocarrier for high-efficiency delivery of various proteins into
mammalian cells.
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